DAFTAR PUSTAKA

Abdel-Misih, S. R. Z., & Bloomston, M. 2010. Liver Anatomy. ***Surgical Clinics of North America***, 90(4), 643–653. https://doi.org/10.1016/j.suc.2010.04.017

Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G. 2010. Epidemiology of Non Alcoholic Fatty Liver Disease**.** ***Digestive Diseases***, 28(1), 155–161. https://doi.org/10.1159/000282080

Bentz, A. B. 2017. A Review of Quercetin: Chemistry, Antioxident Properties, and Bioavailability. **Journal of young investigators**.

Bleby, J., & Festing, M. 1974. The Selection and Supply of Laboratory Animals. In: C.W.Hume (Eds.). ***The UFAW Handbook on the Care and Management of Laboratory Animal, Ed. 4th***, pp. 47-4.

Ble-Castillo, J. L. *et al*. 2012. Differential Effects of High Carbohydrate and High Fat Diet Composition on Metabolic Control and Insulin Resistance in Normal Rats. ***International Journal of Environmental Research and Public Health***, 9(5), pp. 1663–1676. doi: 10.3390/ijerph9051663.

Brown, M. S. and Goldstein, J. L. 2008. Selective Versus Total Insulin Resistance: A Pathogenic Paradox. ***Cell Metabolism***, 7(2), pp. 95–96. doi: 10.1016/j.cmet.2007.12.009.

Byrne, C. D., & Targher, G. 2015. NAFLD: A Multisystem Disease. ***Journal of Hepatology***, 62(S1), S47–S64. https://doi.org/10.1016/j.jhep.2014.12.012

Carr, R. M., Oranu, A., & Khungar, V. 2016. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. ***Gastroenterology Clinics of North America***, 45(4), 639–652. https://doi.org/10.1016/j.gtc.2016.07.003

Cobbina, E., & Akhlaghi, F. 2017. Non-alcoholic fatty liver disease (NAFLD)–Pathogenesis, Classification, and Effect on Drug

Metabolizing Enzymes and Transporters. ***Drug Metabolism Reviews***, 49(2), 197–211. https://doi.org/10.1080/03602532.2017.1293683

Cortez-Pinto, H., & Camilo, M. E. 2004. Non-alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (NAFLD/NASH): Diagnosis and Clinical Course. ***Best Practice and Research: Clinical Gastroenterology***, *18(6 SPEC.ISS.)*, 1089–1104. https://doi.org/10.1016/j.bpg.2004.06.021

Dajas, F., Abin-Carriquiry, J. A., Arredondo, F., Blasina, F., Echeverry, C., Martínez, M., … Vaamonde, L. 2015. Quercetin in Brain Diseases: Potential and Limits. ***Neurochemistry International***, 89, 140–148. https://doi.org/10.1016/j.neuint.2015.07.002

D'Andrea, G. 2015. Quercetin: A flavonol with multifaceted therapeutic applications? ***Fitoterapia***, 106, 256–271. doi:10.1016/j.fitote.2015.09.018

De, A., & Duseja, A. 2019. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. ***Journal of Clinical and Experimental Hepatology***. https://doi.org/10.1016/j.jceh.2019.09.005

Decroli, E., Yerizel, E., & Andam Astari, N. 2015. Gambaran NAFLD pada Pasien dengan Sindrom Metabolik. ***Jurnal Kesehatan Andalas***, *4*(2). Available at: http://download.portalgaruda.org/article.php?article=359532&val=7288&title=Gambaran NAFLD pada Pasien dengan Sindrom Metabolik di Poliklinik Penyakit Dalam RSUP Dr. M. Djamil Padang.

Dias, A. S., Porawski, M., Alonso, M., Marroni, N., Collado, P. S., & González-Gallego, J. 2005. Quercetin Decreases Oxidative Stress, NF-κB Activation, and iNOS Overexpression in Liver of Streptozotocin-Induced Diabetic Rats. ***The Journal of Nutrition***, 135(10), 2299–2304. doi:10.1093/jn/135.10.2299

Du, Z., Yang, Y., Hu, Y., Sun, Y., Zhang, S., Peng, W., … Kong, W. 2012. A Long-term High-fat Diet Increases Oxidative Stress, Mitochondrial Damage and Apoptosis in The Inner Ear of d-galactose-induced Aging Rats. ***Hearing Research***, *287*(1–2), 15–24. https://doi.org/10.1016/j.heares.2012.04.012

Eroschenko, V. P. 2017. ***Atlas of Histology with Functional Correlations***. Wolters Kluwer. https://books.google.co.id/books?id=X3wajwEACAAJ

Ferramosca, A., Di Giacomo, M., & Zara, V. 2017. Antioxidant Dietary Approach in Treatment of Fatty Liver: New Insights and Updates. ***World Journal of Gastroenterology***, 23(23), 4146–4157. https://doi.org/10.3748/wjg.v23.i23.4146

Farrell, G. C., Wong, V. W. S., & Chitturi, S. 2013. NAFLD in Asia as Common and Important as in The West. ***Nature Reviews Gastroenterology and Hepatology***, 10(5), 307–318. https://doi.org/10.1038/nrgastro.2013.34

Gelen, V., Şengül, E., Gedikli, S., Atila, G., Uslu, H., & Makav, M. 2017. The Protective Effect of Rutin and Quercetin on 5-FU-induced Hepatotoxicity in Rats. ***Asian Pacific Journal of Tropical Biomedicine***, *7(7), 647–653.*

Hermanto, S., Muawanah, A., & Harahap, R. 2008. Profil dan Karakteristik Lemak Hewani (Ayam, Sapi dan Babi) Hasil Analisa FTIR dan GCMS. ***Jurnal Kimia VALENSI***, 1(3), 102–109. https://doi.org/10.15408/jkv.v1i3.219

Huang, X., Sun, M., Li, D., Liu, J., Guo, H., Dong, Y., … Li, J. 2011. Augmented NADPH Oxidase Activity and p22phox Expression in Monocytes Underlie Oxidative Stress of Patients with Type 2 Diabetes Mellitus. ***Diabetes Research and Clinical Practice***, 91(3), 371–380. https://doi.org/10.1016/j.diabres.2010.12.026

Horton, J. D. 2002. Sterol Regulatory Element Binding Proteins: Transcriptional Activators of Lipid Synthesis. ***Biochemical Society transactions***, 30, pp. 1091–1095. doi: 10.1042.

Iqbal, U., Perumpail, B., Akhtar, D., Kim, D., & Ahmed, A. 2019. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. ***Medicines***, 6(1), 41. https://doi.org/10.3390/medicines6010041

Jiao, Y., Lu, Y., & Li, X. Y. 2015. Farnesoid X Receptor: A Master Regulator of Hepatic Triglyceride and Glucose Homeostasis. ***Acta Pharmacologica Sinica***, 36(1), 44–50. https://doi.org/10.1038/aps.2014.116

Jornayvaz, F. R., Jurczak, M. J., Lee, H. Y., Birkenfeld, A. L., Frederick, D. W., Zhang, D., Zhang, X. M., Samuel, V. T., & Shulman, G. I. 2010. A High-fat, Ketogenic Diet Causes Hepatic Insulin Resistance in Mice, Despite Increasing Energy Expenditure and Preventing Weight Gain. ***American Journal of Physiology - Endocrinology and Metabolism***, 299(5), 808–815. https://doi.org/10.1152/ajpendo.00361.2010

Jung, C. H., Cho, I., Ahn, J., Jeon, T. Il, & Ha, T. Y. 2013. Quercetin Reduces *High Fat Diet* Induced Fat Accumulation in The Liver by Regulating Lipid Metabolism Genes. ***Phytotherapy Research***, *27*(1), 139–143. https://doi.org/10.1002/ptr.4687

Kammoun, H. L. *et al*. 2009. GRP78 Expression Inhibits Insulin and ER Stress Induced SREBP-1c Activation and Reduces Hepatic Steatosis in Mice. ***The Journal of Clinical investigation***, 119(5), pp. 1201–1215. doi: 10.1172/JCI37007DS1.

Ke, M., & Raju, S. 2014. Comparative Histology of Human and Cow, Goat and Sheep Liver. ***Journal of Surgical Academia***, *4*(1), 10–13.

Kelly, G. S. 2009. Quercitin. ***Dictionary of Gems and Gemology***, 16(2), 708–708. https://doi.org/10.1007/978-3-540-72816-0_17927

Kim, S. G., Kim, B. K., Kim, K., & Fang, S. 2016. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease. ***Endocrinology and Metabolism***, 31(4), 500–504. https://doi.org/10.3803/EnM.2016.31.4.500

Kohjima, M., Higuchi, N., Kato, M., Kotoh, K., Yoshimoto, T., Fujino, T., … Nakamuta, M. 2008. SREBP-1c, Regulated by The Insulin and AMPK Signaling Pathways, Plays a Role in Nonalcoholic Fatty Liver Disease. ***International Journal of Molecular Medicine***. doi:10.3892/ijmm.21.4.507

Kobori M, Masumoto S, Akimoto Y, Oike H. 2011. Chronic Dietary Intake of Quercetin Alleviates Hepatic Fat Accumulation Associated with Consumption of a Western-Style Diet in C57/BL6J Mice. ***Mol Nutr Food Res*** 55(4): 530-540.

Koo, S. H. 2013. Nonalcoholic Fatty Liver Disease: Molecular Mechanisms for The Hepatic Steatosis. ***Clinical and Molecular Hepatology***, *19*(3), 210–215. https://doi.org/10.3350/cmh.2013.19.3.210

Lakhanpal, P., & Rai, D. K. 2007. Quercetin: A Versatile Flavonoid. ***Internet Journal of Medical Update-EJOURNAL***, 2(2), 22–37. https://doi.org/10.4314/ijmu.v2i2.39851

Lefkowitch, J. H. 2018. Chapter 1 Anatomy and Function. ***Sherlock's Diseases of the Liver and Biliary System, 12th Edition***, 1–19.

Levene, A. P., & Goldin, R. D. 2012. The Epidemiology, Pathogenesis and Histopathology of Fatty Liver Disease. ***Histopathology***, *61*(2), 141–152. https://doi.org/10.1111/j.1365-2559.2011.04145.x

Lewis, J. R., & Mohanty, S. R. 2010. Nonalcoholic Fatty Liver Disease: A Review and Update. ***Digestive Diseases and Sciences***, 55(3), 560–578. https://doi.org/10.1007/s10620-009-1081-0

Li, Q., Dhyani, M., Grajo, J. R., Sirlin, C., & Samir, A. E. 2018. Current Status of Imaging in Nonalcoholic Fatty Liver Disease. ***World Journal of Hepatology***, 10(8), 530–542. https://doi.org/10.4254/wjh.v10.i8.530

Li, S., Tan, H. Y., Wang, N., Cheung, F., Hong, M., & Feng, Y. 2018. The Potential and Action Mechanism of Polyphenols in the Treatment of Liver Diseases. ***Oxidative Medicine and Cellular Longevity***, 2018. doi: 10.1155/2018/8394818.

Li, X., Wang, R., Zhou, N., Wang, X., Liu, Q., Bai, Y., Shi, T. 2013. Quercetin Improves Insulin Resistance and Hepatic Lipid Accumulation in Vitro in a NAFLD Cell Model. ***Biomedical Reports***, *1*(1), 71–76. https://doi.org/10.3892/br.2012.27

Long, Y. C. *et al*. 2006. AMP-activated Protein Kinase Signaling in Metabolic Regulation Find the Latest Version : Review Series AMP-activated Protein Kinase Signaling in Metabolic Regulation, 116(7), pp. 1776–1783. doi: 10.1172/JCI29044.1776.

Malarkey, D. E., Johnson, K., Ryan, L., Boorman, G., & Maronpot, R. 2005. New Insights into Functional Aspects of Liver Morphology. ***Toxicologic Pathology***, *33*(1), 27–34. https://doi.org/10.1080/01926230590881826

Mariani, C *et al*. 2008 Flavonoid Characterization and *In Vitro* Antioxidant Activity of *Aconitum anthora* L. (Ranunculaceae). ***Phytochemistry*** 69: 1220-1226

Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., … Melchionda, N. 2001. Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome. ***Diabetes***, *50(8), 1844–1850*. doi:10.2337/diabetes.50.8.1844

Masarone, M., Rosato, V., Dallio, M., & Gravina, A. G. 2018. Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. ***Oxidative Medicine and Cellular Longevity***, 2018, 9547613. https://doi. org/10.1155/2018/9547613

Mescher, Anthony. 2016. ***Junqueira's Basic Histology Text & Atlas (14th ed.)***.

Mishra, A., & Younossi, Z. M. 2012. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. ***Journal of Clinical and Experimental Hepatology***, 2(2), 135–144. https://doi.org/10.1016/S0973-6883(12)60102-9

Miura, S., & Suzuki, A. 2020. Induction of Steatohepatitis and Liver Tumorigenesis by Enforced Snail Expression in Hepatocytes. ***American Journal of Pathology***, *190*(6), 1271–1283. https://doi.org/10.1016/j.ajpath.2020.02.005

Mori, T., Imaida, K., Tamano, S., Sano, M., Takahashi, S., Asamoto, M., … Shirai, T. 2001. Beef tallow, but not Perilla or Corn Oil, Promotion of Rat Prostate and Intestinal Carcinogenesis by 3,2-dimethyl-4-aminobiphenyl. ***Japanese Journal of Cancer Research***, 92(10), 1026–1033. https://doi.org/10.1111/j.1349-7006.2001.tb01056.x

Paradies, G., Paradies, V., Ruggiero, F. M., & Petrosillo, G. 2014. Oxidative Stress, Cardiolipin and Mitochondrial Dysfunction in Nonalcoholic Fatty Liver Disease. ***World Journal of Gastroenterology***, 20(39), 14205–14218. https://doi.org/10.3748/wjg.v20.i39.14205

Park, J. G. *et al.* 2016. CREBH-FGF21 Axis Improves Hepatic Steatosis by Suppressing Adipose Tissue Lipolysis, ***Scientific Reports***, 6(June), pp. 1–13. doi: 10.1038/srep27938.

Porras, D., Nistal, E., Martínez-Flórez, S., Pisonero-Vaquero, S., Olcoz, J. L., Jover, R., González-Gallego, J., García-Mediavilla, M. V., & Sánchez-Campos, S. 2017. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. ***Free Radical Biology and Medicine***, *102* (November 2016), 188–202. https://doi.org/10.1016/j.freeradbiomed.2016.11.037

Romero-Gómez, M., Zelber-Sagi, S. and Trenell, M. 2017. Treatment of NAFLD with Diet, Physical Activity and Exercise, ***Journal of Hepatology***, 67(4), pp. 829–846. doi: 10.1016/j.jhep.2017.05.016.

Rosqvist, F., Iggman, D., Kullberg, J., Cedernaes, J., Johansson, H.-E., Larsson, A., … Riserus, U. (2014). Overfeeding Polyunsaturated and Saturated Fat Causes Distinct Effects on Liver and Visceral Fat Accumulation in Humans. **Diabetes**, 63(7), 2356–2368. https://doi.org/10.2337/db13-1622

Schwenger, K. J. P., & Allard, J. P. 2014. Clinical Approaches to Non-alcoholic Fatty Liver Disease. ***World Journal of Gastroenterology***, 20(7), 1712–1723. https://doi.org/10.3748/wjg.v20.i7.1712

Song, Z., Xiaoli, A. M., & Yang, F. 2018. Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues. ***Nutrients***, 10(10), 1–22. https://doi.org/10.3390/nu10101383

Takahashi, Y., & Fukusato, T. 2014. Histopathology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. ***World Journal of Gastroenterology***, 20(42), 15539–15548. https://doi.org/10.3748/wjg.v20.i42.15539

Takaki, A., Kawai, D., & Yamamoto, K. 2013. Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-alcoholic Steatohepatitis (NASH). ***International Journal of Molecular Sciences***, 14(10), 20704–20728. https://doi.org/10.3390/ijms141020704

Tan, B. L. and Norhaizan, M. E. 2019. Effect of High-fat Diets on Oxidative Stress, Cellular Inflammatory Response and Cognitive Function', ***Nutrients***, 11(11), pp. 1–22. doi: 10.3390/nu11112579.

Valdés, Paloma Almeda., Ramos, Daniel Cuevas & Salinas, Carlos Alberto Aguilar. 2009. Non Alcoholic Fatty Liver Disease and Metabolic

Syndrome. ***Hippokratia***, 13(1), 9–19. https://doi.org/10.1016/s1665-2681(19)31822-8

Wakim, K. G. 2017. Physiology of The Liver. ***The American Journal of Medicine***, 16(2), 256–271. https://doi.org/10.1016/0002-9343(54)90342-3

Wang, W., Wang, C., Ding, X.-Q., Pan, Y., Gu, T.-T., Wang, M.-X., … Kong, L.-D. 2013. Quercetin and Allopurinol Reduce Liver Thioredoxin-Interacting Protein to Alleviate Inflammation and Lipid Accumulation in Diabetic Rats. ***British Journal of Pharmacology***, 169(6), pp. 1352–1371. doi: 10.1111/bph.12226.

Watanabe, M. *et al*. 2004. Bile Acids Lower Triglyceride Levels via a Pathway Involving FXR, SHP, and SREBP-1c. ***Journal of Clinical Investigation***, 113(10), 1408–1418. https://doi.org/10.1172/JCI21025

Xu, Y. *et al*. 2019. Metabolomics Characterizes The Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development, ***International Journal of Molecular Sciences***, 20(5). doi: 10.3390/ijms20051220.

Xu, J. Y., Li, Z. P., Zhang, L., & Ji, G. 2014. Recent Insights into Farnesoid X Receptor in Non-alcoholic Fatty Liver Disease. ***World Journal of Gastroenterology***, 20(37), 13493–13500. https://doi.org/10.3748/wjg.v20.i37.13493

Xi, Y., & Li, H. 2020. Role of Farnesoid X Receptor in Hepatic Steatosis in Nonalcoholic Fatty Liver Disease. ***Biomedicine & Pharmacotherapy***, 121, 109609. doi:10.1016/j.biopha.2019.109609

Zha, B. S. and Zhou, H. 2012. ER stress and lipid metabolism in adipocytes. ***Biochemistry Research International***, 2012. doi: 10.1155/2012/312943.

Zainuddin, M., 2014. ***Metodologi Penelitian Kefarmasian dan Kesehatan.*** Edisi ke-2, Surabaya: Airlangga University Press